Binuclear manganese(II) complexes based on pyridyl-containing dialkylphosphine oxides

Enikeeva, Kamila R.; Shamsieva, Aliia V.; Kasimov, Airat I.; Fayzullin, Robert R.; Litvinov, Igor A.; Khrizanforova, Vera V.; Budnikova, Yulia H.; Lyubina, Anna P.; Voloshina, Alexandra D.; Kolesnikov, Ilya E.; Musina, Elvira I.; Karasik, Andrey A.

doi:10.1016/j.ica.2023.121741

Cited by 4 publications

(2 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…K.R. Enikeeva and coworkers have synthesized manganese(II) complexes (Enikeeva, et al, 2023) (Figure 1; 4, 5, 6) with Mn 2 Cl 2 and more rare Mn 2 O 2 cores based on the diisopropyl (pyridin-2-yl) phosphine oxide and diethyl (pyridin-2-yl)phosphine oxide ligands.…”

Section: Anticancer Activitymentioning

confidence: 99%

“…The cytotoxic effect of these Mn complexes on the HeLa (cervical carcinoma) and HuTu80 (intestine) cancer cell lines and Chang liver normal cell lines has been studied. It was found that Mn(II) complex 5 with the Mn 2 O 2 core was the effective hydrogen catalyst and exhibited high cytotoxicity towards the cancer HuTu80 cell line (selectivity index = 7.6) and very low toxicity against healthy Chang liver cells, making it very promising for further biomedical studies (Enikeeva, et al, 2023). However, the Authors did not study the precise mode of action of those complexes, so it is hard to speculate if ROS had any impact on cancer cell death.…”

Section: Anticancer Activitymentioning

confidence: 99%

See 1 more Smart Citation

Can Mn coordination compounds be good candidates for medical applications?

Kozieł,

Wojtala,

Szmitka

et al. 2024

Front. Chem. Biol.

View full text Add to dashboard Cite

Metal centres provide unique foci for varied biological modes of action that often but not exclusively involve redox or metal-ligand reactions. Metal complexes offer alternative and flexible coordination geometries, electron and proton transfer sites, inner and outer sphere reactivities, sites for redox-active, hemi-labile, and non-innocent ligands, and a variety of potentially controllable properties for exploitation in a therapeutic or biological context. The discovery of the first anticancer, the metal-based compound cisplatin in 1965 by Barnett Rosenberg was a historical outstanding breakthrough and led to a new area of metal-drug discovery. Some metal-based compounds have FDA approval for clinical use, while some undergo clinical trials for various medical therapies. This mini-review focuses on recent progress on Mn-based complexes with potential anticancer, antibacterial, and antifungal activities.

show abstract

Section: Anticancer Activitymentioning

confidence: 99%

Section: Anticancer Activitymentioning

confidence: 99%